Journal: American Journal of Translational Research

Article Title: microRNA-1246 mediates lipopolysaccharide-induced pulmonary endothelial cell apoptosis and acute lung injury by targeting angiotensin-converting enzyme 2

doi:

Figure Lengend Snippet: LPS induces miR-1246 to target ACE2 expression in PMVECs. A: qRT-PCR analysis of miR-1246 expression in PMVECs treated with LPS or vehicle control. *P < 0.05 vs. vehicle. B: Western blot analysis of ACE2 protein in PMVECs transfected with miR-1246 mimic or negative control miRNA. Bar graphs (bottom) show densitometric analysis of ACE2 protein. *P < 0.05 vs. vehicle. C: Luciferase reporter assay showed that miR-1246 repressed the expression of the luciferase reporter containing the wild-type (wt) but not mutated (mut) ACE2 3’-UTR. The predicted target site for miR-1246 in the ACE2 3’-UTR is shown in top panels. *P < 0.05 vs. vehicle. D: Western blot analysis of ACE2 protein in PMVECs pretransfected with anti-miR-1246 or control inhibitors before exposure to LPS. *P < 0.05.

Article Snippet: Cell culture and LPS treatment Human PMVECs were purchased from ScienCell Research Laboratories, Inc. (Carlsbad, CA, USA) and cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS; GE Healthcare HyClone, Logan, UT, USA).

Techniques: Expressing, Quantitative RT-PCR, Control, Western Blot, Transfection, Negative Control, Luciferase, Reporter Assay

Journal: American Journal of Translational Research

Article Title: microRNA-1246 mediates lipopolysaccharide-induced pulmonary endothelial cell apoptosis and acute lung injury by targeting angiotensin-converting enzyme 2

doi:

Figure Lengend Snippet: miR-1246 is involved in LPS-triggered apoptosis and inflammatory response in PMVECs. A: TUNEL staining of PMVECs pretransfected with anti-miR-1246 or control inhibitors (C-inhibitor) before exposure to LPS. Scale bar, 50 μm. *P < 0.05. B: ELISA analysis of IL-1β and TNF-α levels in conditioned medium from PMVECs with indicated treatments. *P < 0.05. C: TUNEL staining of PMVECs transfected with miR-1246 mimic or negative control miRNA. Scale bar, 50 μm. D: Measurement of IL-1β and TNF-α levels in conditioned medium from PMVECs transfected with miR-1246 mimic or negative control miRNA. *P < 0.05 vs. control.

Article Snippet: Cell culture and LPS treatment Human PMVECs were purchased from ScienCell Research Laboratories, Inc. (Carlsbad, CA, USA) and cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS; GE Healthcare HyClone, Logan, UT, USA).

Techniques: TUNEL Assay, Staining, Control, Enzyme-linked Immunosorbent Assay, Transfection, Negative Control

Journal: American Journal of Translational Research

Article Title: microRNA-1246 mediates lipopolysaccharide-induced pulmonary endothelial cell apoptosis and acute lung injury by targeting angiotensin-converting enzyme 2

doi:

Figure Lengend Snippet: miR-1246 promotes PMVEC apoptosis by repressing ACE2 expression. A: Western blot analysis of ACE2 protein in PMVECs transfected with indicated constructs. B: Detection of apoptosis by TUNEL staining in PMVECs transfected with indicated constructs. *P < 0.05. C: Western blot analysis of Bcl-2, Bcl-xL, and Bax proteins in PMVECs transfected with indicated constructs.

Article Snippet: Cell culture and LPS treatment Human PMVECs were purchased from ScienCell Research Laboratories, Inc. (Carlsbad, CA, USA) and cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS; GE Healthcare HyClone, Logan, UT, USA).

Techniques: Expressing, Western Blot, Transfection, Construct, TUNEL Assay, Staining

Journal: Advanced Science

Article Title: Pulmonary‐Targeted Nanoparticles Interrupt the Malignant Mechanical and Biochemical Signaling Crosstalk for Idiopathic Pulmonary Fibrosis Therapy

doi: 10.1002/advs.202512658

Figure Lengend Snippet: Characterization and multifunctional properties of the VB‐RT NPs. A) Particle size of different formulations. B) Zeta potential of different formulations. C‐D) Average size distribution and TEM images of VB NPs and VB‐RT NPs. E) UV–vis spectra of different formulations across the full wavelength range. F) Seven‐day stability of VB NPs, VB‐R NPs, and VB‐RT NPs. G) Comparison of particle size before and after nebulization. H) Heatmap of PDI before and after nebulization. I) Fluorescence imaging of ROS levels in 16HBE cells under different formulations using DCFH DA. J) The NO detection in 16HBE cells under different formulations using DAF‐FM DA. K) Quantification of mean fluorescence intensity (MFI) of NO in 16HBE cells under different formulations (n = 3). L) Uptake of different formulations in PMVECs measured by flow cytometry. M) Quantification of MFI of NO in A549 cells under different formulations using DAF‐FM DA (n = 3). N) Illustration of the in vitro collagen barrier model, showing DiI‐labeled NPs crossing the epithelial cell‐collagen layer to reach myofibroblasts. O) CLSM images of myofibroblasts treated with different formulations in Transwell chambers with collagen barrier for 4 h at 37 °C. P) Quantification of MFI in myofibroblasts analyzed using ImageJ (n = 3). All data are presented as the Mean ± SD (n = 3). *** p < 0.001.

Article Snippet: PMVECs were purchased from ProCell, and 16HBE cells were obtained from ATCC (Shanghai, China).

Techniques: Zeta Potential Analyzer, Comparison, Fluorescence, Imaging, Flow Cytometry, In Vitro, Labeling